Table 1.
Loci and alleles detected by the assays.
Table 2.
Haplotype calls of 10 HapMap samples used for assay validation.
Table 3.
Allele frequencies in Malay, Chinese and Indian subjects.
Table 4.
Diplotype frequencies and functional classification of CYP2C9, CYP2C19, CYP2D6, CYP3A5 and VKORC1 in the Singapore population (n = 506).
Fig 1.
Frequency of metabolizer groups in 3 major ethnic groups of Singapore population.
(A) CYP2C9 (B) CYP2C19 and (C) CYP2D6.
Table 5.
Frequencies of CYP2D6 copy numbers in the Singapore population tested.
Fig 2.
The frequencies of actionable diplotypes for each drug-gene rule.
The definition of actionable diplotypes is defined as follows: (i) warfarin, CYP2C9 *2 or *3 heterozygote or homozygote with VKORC1 GA or AA genotype and CYP2C9*1 with VKORC1 AA genotype; (ii) clopidogrel, CYP2C19*2, *3 and *6; (iii) codeine, CYP2D6 poor and intermediate metabolizers; (iv) tacrolimus, CYP3A5*1 heterozygote or homozygote.
Table 6.
Recommendations for actionable pharmacogenomic markers based on CPIC guidelines.